Literature DB >> 34697082

Transcriptional Regulation of Carboxylesterase 1 in Human Liver: Role of the Nuclear Receptor Subfamily 1 Group H Member 3 and Its Splice Isoforms.

Joseph M Collins1, Rong Lu1, Xinwen Wang1, Hao-Jie Zhu1, Danxin Wang2.   

Abstract

Carboxylesterase 1 (CES1) is the predominant carboxylesterase in the human liver, involved in metabolism of both xenobiotics and endogenous substrates. Genetic or epigenetic factors that alter CES1 activity or expression are associated with changes in drug response, lipid, and glucose homeostasis. However, the transcriptional regulation of CES1 in the human liver remains uncertain. By applying both the random forest and Sobol's Sensitivity Indices (SSI) to analyze existing liver RNA expression microarray data (GSE9588), we identified nuclear receptor subfamily 1 group H member 3 (NR1H3) liver X receptor (LXR)α as a key factor regulating constitutive CES1 expression. This model prediction was validated using small interfering RNA (siRNA) knockdown and CRISPR-mediated transcriptional activation of NR1H3 in Huh7 and HepG2 cells. We found that NR1H3's activation of CES1 is splice isoform-specific, namely that increased expression of the NR1H3-211 isoform increased CES1 expression whereas NR1H3-201 did not. Also, in human liver samples, expression of NR1H3-211 and CES1 are correlated, whereas NR1H3-201 and CES1 are not. This trend also occurs during differentiation of induced pluripotent stem cells (iPSCs) to hepatocytes, where only expression of the NR1H3-211 isoform parallels expression of CES1 Moreover, we found that treatment with the NR1H3 agonist T0901317 in HepG2 cells had no effect on CES1 expression. Overall, our results demonstrate a key role of NR1H3 in maintaining the constitutive expression of CES1 in the human liver. Furthermore, our results support that the effect of NR1H3 is splice isoform-specific and appears to be ligand independent. SIGNIFICANCE STATEMENT: Despite the central role of carboxylesterase 1 (CES1) in metabolism of numerous medications, little is known about its transcriptional regulation. This study identifies nuclear receptor subfamily 1 group H member 3 as a key regulator of constitutive CES1 expression and therefore is a potential target for future studies to understand interperson variabilities in CES1 activity and drug metabolism.
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34697082      PMCID: PMC8969197          DOI: 10.1124/dmd.121.000649

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  38 in total

1.  Transcription factor-mediated regulation of carboxylesterase enzymes in livers of mice.

Authors:  Youcai Zhang; Xingguo Cheng; Lauren Aleksunes; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2012-03-19       Impact factor: 3.922

2.  17β-estradiol suppresses carboxylesterases by activating c-Jun/AP-1 pathway in primary human and mouse hepatocytes.

Authors:  Lili Wu; Muhammad Zubair Hafiz; Yu Guan; Shuangcheng He; Jing Xiong; Wei Liu; Bingfang Yan; Xiaoping Li; Jian Yang
Journal:  Eur J Pharmacol       Date:  2017-11-23       Impact factor: 4.432

3.  Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.

Authors:  R Humerickhouse; K Lohrbach; L Li; W F Bosron; M E Dolan
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

4.  Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex.

Authors:  Silvana Konermann; Mark D Brigham; Alexandro E Trevino; Julia Joung; Omar O Abudayyeh; Clea Barcena; Patrick D Hsu; Naomi Habib; Jonathan S Gootenberg; Hiroshi Nishimasu; Osamu Nureki; Feng Zhang
Journal:  Nature       Date:  2014-12-10       Impact factor: 49.962

5.  Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.

Authors:  Jian Shi; Xinwen Wang; Jenny-Hoa Nguyen; Barry E Bleske; Yan Liang; Li Liu; Hao-Jie Zhu
Journal:  Biochem Pharmacol       Date:  2016-09-08       Impact factor: 5.858

6.  In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors.

Authors:  Ragnar Thomsen; Henrik B Rasmussen; Kristian Linnet
Journal:  Drug Metab Dispos       Date:  2013-10-18       Impact factor: 3.922

7.  Fluoxetine reduces CES1, CES2, and CYP3A4 expression through decreasing PXR and increasing DEC1 in HepG2 cells.

Authors:  Wei Shang; Jie Liu; Ruini Chen; Rui Ning; Jing Xiong; Wei Liu; Zhao Mao; Gang Hu; Jian Yang
Journal:  Xenobiotica       Date:  2015-09-04       Impact factor: 1.908

8.  Human cytochrome P450 1A1 is a novel target gene of liver X receptor α.

Authors:  Norihito Shibahara; Yuiko Masunaga; Shunsuke Iwano; Hiroshi Yamazaki; Kazuma Kiyotani; Tetsuya Kamataki
Journal:  Drug Metab Pharmacokinet       Date:  2011-06-07       Impact factor: 3.614

Review 9.  Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.

Authors:  Jessica C Song; C Michael White
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 5.577

10.  Ensembl 2021.

Authors:  Kevin L Howe; Premanand Achuthan; James Allen; Jamie Allen; Jorge Alvarez-Jarreta; M Ridwan Amode; Irina M Armean; Andrey G Azov; Ruth Bennett; Jyothish Bhai; Konstantinos Billis; Sanjay Boddu; Mehrnaz Charkhchi; Carla Cummins; Luca Da Rin Fioretto; Claire Davidson; Kamalkumar Dodiya; Bilal El Houdaigui; Reham Fatima; Astrid Gall; Carlos Garcia Giron; Tiago Grego; Cristina Guijarro-Clarke; Leanne Haggerty; Anmol Hemrom; Thibaut Hourlier; Osagie G Izuogu; Thomas Juettemann; Vinay Kaikala; Mike Kay; Ilias Lavidas; Tuan Le; Diana Lemos; Jose Gonzalez Martinez; José Carlos Marugán; Thomas Maurel; Aoife C McMahon; Shamika Mohanan; Benjamin Moore; Matthieu Muffato; Denye N Oheh; Dimitrios Paraschas; Anne Parker; Andrew Parton; Irina Prosovetskaia; Manoj P Sakthivel; Ahamed I Abdul Salam; Bianca M Schmitt; Helen Schuilenburg; Dan Sheppard; Emily Steed; Michal Szpak; Marek Szuba; Kieron Taylor; Anja Thormann; Glen Threadgold; Brandon Walts; Andrea Winterbottom; Marc Chakiachvili; Ameya Chaubal; Nishadi De Silva; Bethany Flint; Adam Frankish; Sarah E Hunt; Garth R IIsley; Nick Langridge; Jane E Loveland; Fergal J Martin; Jonathan M Mudge; Joanella Morales; Emily Perry; Magali Ruffier; John Tate; David Thybert; Stephen J Trevanion; Fiona Cunningham; Andrew D Yates; Daniel R Zerbino; Paul Flicek
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.